the acelrx first quarter 2009 conference call is being webcast on the events page of the investors section of the investors section of the investors sections of the investors section of the investors page of the investors section of the investor to improve the quality of the meeting. the first quarter is a week after the launch of the drug, a new drug that is a noninvasive and noninvasive route of administration that allows for rapid onset and blunted peak plasma levels and duration of action without active metabolites. the first quarter is a quarter of the launch and is a second priority for the year. we are excited by the number of hospitals that we are having active discussions to bring the drug onto its formulary. we have successfully completed or scheduled 46 formulary reviews by mid-year. we continue to track to achieving 125 formulary approvals by the end of the year. we continue to track to achieving the target 125 formulary approvals by the end the year. we continue to track to achieve 125 formulary approvals by the end. we continue to track to achieving these goals by the end of the year.